Rhubarb Polysaccharide and Berberine Co-assembled Nanoparticles Ameliorate Ulcerative Colitis by Regulating the Intestinal Flora

Overview

Journal Front Pharmacol

Date 2023 Jul 6

PMID 37408766

Authors

Yifan Feng

Chenyang Wu

Huan Chen

Tingting Zheng

Hanyi Ye

Jinrui Wang

Yinghua Zhang

Jia Gao

Ying Li

Zhengqi Dong

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) affects about 7 million people globally, which is a chronic inflammatory condition of the gastrointestinal tract caused by gut microbiota alterations, immune dysregulation, genetic and environmental factors. Nanoparticles (NPs) deliver an active natural compound to a site harbored by disordered microbiota, they are used to interact, target and act intentionally on microbiota. Although there is accumulating evidence indicating that berberine and polysaccharide play an important role in IBD via regulating microbiota, there is limited research that presents a complete picture of exactly how their carrier-free co-assembled nanodrug affects IBD. The study establishes the carrier-free NPs formed by berberine and rhubarb polysaccharide based on the combination theory of and , and characterizes the NPs. The IBD treatment efficacy of NPs are evaluated via IBD efficacy index, and explore the mechanism of NPs via 16S rRNA test and immunohistochemistry including occludin and zonula occludens-1. The results showed that DHP and BBR were co-assembled to nanoparticles, and the BD can effectively relieve the symptoms of UC mouse induced by DSS via regulating gut microbiota and repair the gut barrier integrity, because BD have a longer retention on the colon tissue and react with the microbiota and mucus thoroughly. Interestingly, BD can enrich more probiotic than free BBR and DHP. This design provides a better strategy and encourages future studies on IBD treatment via regulating gut microbiota and the design of novel plant polysaccharide based carrier-free co-assembly therapies.

Citing Articles

The Potential Role of Plant Polysaccharides in Treatment of Ulcerative Colitis.

Dilixiati Y, Aipire A, Song M, Nijat D, Wubuli A, Cao Q Pharmaceutics. 2024; 16(8).

PMID: 39204418 PMC: 11360206. DOI: 10.3390/pharmaceutics16081073.

Antitumor immunostimulatory activity of the traditional Chinese medicine polysaccharide on hepatocellular carcinoma.

Liu Y, Wu J, Hao H Front Immunol. 2024; 15:1369110.

PMID: 38455058 PMC: 10917928. DOI: 10.3389/fimmu.2024.1369110.

References

Grander C, Adolph T, Wieser V, Lowe P, Wrzosek L, Gyongyosi B . Recovery of ethanol-induced depletion ameliorates alcoholic liver disease. Gut. 2017; 67(5):891-901. DOI: 10.1136/gutjnl-2016-313432. View

Ishikawa D, Sasaki T, Osada T, Kuwahara-Arai K, Haga K, Shibuya T . Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis. Inflamm Bowel Dis. 2016; 23(1):116-125. DOI: 10.1097/MIB.0000000000000975. View

Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H . Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. Digestion. 2016; 93(1):59-65. DOI: 10.1159/000441768. View

Zhang W, Xu J, Yu T, Chen Q . Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. Biomed Pharmacother. 2019; 118:109131. DOI: 10.1016/j.biopha.2019.109131. View

Zhao Q, Luan X, Zheng M, Tian X, Zhao J, Zhang W . Synergistic Mechanisms of Constituents in Herbal Extracts during Intestinal Absorption: Focus on Natural Occurring Nanoparticles. Pharmaceutics. 2020; 12(2). PMC: 7076514. DOI: 10.3390/pharmaceutics12020128. View

Bergstrom K, Liu X, Zhao Y, Gao N, Wu Q, Song K . Defective Intestinal Mucin-Type O-Glycosylation Causes Spontaneous Colitis-Associated Cancer in Mice. Gastroenterology. 2016; 151(1):152-164.e11. PMC: 5068133. DOI: 10.1053/j.gastro.2016.03.039. View

Larsson J, Karlsson H, Crespo J, Johansson M, Eklund L, Sjovall H . Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm Bowel Dis. 2011; 17(11):2299-307. DOI: 10.1002/ibd.21625. View

Da Silva S, Robbe-Masselot C, Ait-Belgnaoui A, Mancuso A, Mercade-Loubiere M, Salvador-Cartier C . Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment. Am J Physiol Gastrointest Liver Physiol. 2014; 307(4):G420-9. DOI: 10.1152/ajpgi.00290.2013. View

Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H . Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013; 500(7461):232-6. DOI: 10.1038/nature12331. View

10.

Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A . Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2017; 11(1):1-10. DOI: 10.1007/s12328-017-0813-5. View

11.

Timpte C, Eckhardt A, ABERNETHY J, Hill R . Porcine submaxillary gland apomucin contains tandemly repeated, identical sequences of 81 residues. J Biol Chem. 1988; 263(2):1081-8. View

12.

Zhang Y, Wang L, Ocansey D, Wang B, Wang L, Xu Z . Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease. J Inflamm Res. 2021; 14:5939-5953. PMC: 8598207. DOI: 10.2147/JIR.S327609. View

13.

Fan Y, Pedersen O . Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2020; 19(1):55-71. DOI: 10.1038/s41579-020-0433-9. View

14.

Roy S, Trinchieri G . Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017; 17(5):271-285. DOI: 10.1038/nrc.2017.13. View

15.

Ma B, Yin C, Zhang B, Dai Y, Jia Y, Yang Y . Naturally occurring proteinaceous nanoparticles in Coptidis Rhizoma extract act as concentration-dependent carriers that facilitate berberine absorption. Sci Rep. 2016; 6:20110. PMC: 4731763. DOI: 10.1038/srep20110. View

16.

Wu J, Wei Z, Cheng P, Qian C, Xu F, Yang Y . Rhein modulates host purine metabolism in intestine through gut microbiota and ameliorates experimental colitis. Theranostics. 2020; 10(23):10665-10679. PMC: 7482825. DOI: 10.7150/thno.43528. View

17.

Cui H, Cai Y, Wang L, Jia B, Li J, Zhao S . Berberine Regulates Treg/Th17 Balance to Treat Ulcerative Colitis Through Modulating the Gut Microbiota in the Colon. Front Pharmacol. 2018; 9:571. PMC: 5991375. DOI: 10.3389/fphar.2018.00571. View

18.

Wu C, Zheng T, Chen H, Zou P, Zhang M, Wang J . Effect and Mechanism of Pharmaceutical Excipients on Berberine to Alleviate Ulcerative Colitis via Regulating Gut Microbiota. Molecules. 2022; 27(18). PMC: 9503871. DOI: 10.3390/molecules27185997. View

19.

Corfield A, Berry M . Glycan variation and evolution in the eukaryotes. Trends Biochem Sci. 2015; 40(7):351-9. DOI: 10.1016/j.tibs.2015.04.004. View

20.

Hale M . Radiation enteritis: from diagnosis to management. Curr Opin Gastroenterol. 2020; 36(3):208-214. DOI: 10.1097/MOG.0000000000000632. View